Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07389239 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.
A Phase 1 study, sponsored by University of Chicago.
- Not yet
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT07389239: Clinical Trial Phase 1 study, sponsored by University of Chicago.
NCT07389239 is a Phase 1 study that has not yet begun recruiting, run by University of Chicago. The registered enrollment target is 24 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07389239, a Phase 1 study, has not yet begun recruiting, sponsored by University of Chicago.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This phase I/IIA trial studies the side effects and best dose of gene-modified T cells when given with or without decitabine, and to see how well they work in treating patients with malignancies expressing cancer-testis antigens.
Primary Outcome
To evaluate the safety and tolerability of the autologous NY-ESO-1/ dnTGFβRII engineered T cell therapy in combination with decitabine and low-dose IL2 in patients with advanced malignancies. The irRECIST will be used for tumor response assessment performed at 6 weeks, 3 months, 6 months and 9 months.
Interventions
- DRUG Decitabine
- DRUG Aldesleukin
- DRUG Cyclophosphamide Conditioning
- BIOLOGICAL NY-ESO-1 TCR/ dnTGFβRII
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-06-23 |
| Est. Completion | 2031-12-10 |
| Phase | Phase 1 |
What is known before NCT07389239 opens enrollment
NCT07389239 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 4 interventions - of which Decitabine is the first listed.
NCT07389239 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07389239 about?
NCT07389239 is a clinical study titled "A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.". This phase I/IIA trial studies the side effects and best dose of gene-modified T cells when given with or without decitabine, and to see how well they work in treating patients with malignancies expressing cancer-testis antigens.
What is the current status of trial NCT07389239?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2026-06-23. Estimated completion is 2031-12-10.
What interventions are being tested in trial NCT07389239?
The interventions under investigation include: Decitabine (DRUG), Aldesleukin (DRUG), Cyclophosphamide Conditioning (DRUG), NY-ESO-1 TCR/ dnTGFβRII (BIOLOGICAL).
Who is sponsoring clinical trial NCT07389239?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07389239's enrollment target sits among peer trials
24 1520th of 2000 higher than 405 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI